CN108697795A - Gfral受体疗法 - Google Patents
Gfral受体疗法 Download PDFInfo
- Publication number
- CN108697795A CN108697795A CN201680082844.2A CN201680082844A CN108697795A CN 108697795 A CN108697795 A CN 108697795A CN 201680082844 A CN201680082844 A CN 201680082844A CN 108697795 A CN108697795 A CN 108697795A
- Authority
- CN
- China
- Prior art keywords
- gfral
- leu
- compound
- receptors
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2016/074809 WO2017147742A1 (en) | 2016-02-29 | 2016-02-29 | Gfral receptor therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108697795A true CN108697795A (zh) | 2018-10-23 |
Family
ID=59742416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680082844.2A Pending CN108697795A (zh) | 2016-02-29 | 2016-02-29 | Gfral受体疗法 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3423094A4 (ro) |
JP (1) | JP2019510739A (ro) |
CN (1) | CN108697795A (ro) |
WO (1) | WO2017147742A1 (ro) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109069636A (zh) * | 2016-03-04 | 2018-12-21 | 恩格姆生物制药公司 | 用于调节体重的组合物和方法 |
WO2023274276A1 (zh) * | 2021-06-30 | 2023-01-05 | 上海津曼特生物科技有限公司 | 抗gfral抗体及其应用 |
CN116444667A (zh) * | 2023-06-13 | 2023-07-18 | 上海驯鹿生物技术有限公司 | 一种靶向gdf15的全人源抗体及其应用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012240102C1 (en) | 2011-04-08 | 2016-09-08 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
WO2017172260A1 (en) | 2016-03-31 | 2017-10-05 | Ngm Bioparmaceuticals, Inc. | Binding proteins and methods of use thereof |
CA3038846A1 (en) * | 2016-10-12 | 2018-04-19 | Janssen Biotech, Inc. | Methods for screening for modulators of gdf15-like biological activity |
TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
PE20211078A1 (es) * | 2018-10-22 | 2021-06-09 | Janssen Pharmaceutica Nv | Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas |
EP4041722A4 (en) | 2019-10-07 | 2023-12-13 | Kallyope, Inc. | GPR119 AGONISTS |
CN116323608A (zh) | 2020-05-19 | 2023-06-23 | 卡尔优普公司 | Ampk活化剂 |
AU2021284131A1 (en) * | 2020-06-04 | 2023-02-09 | Daegu Gyeongbuk Institute Of Science And Technology | GFRAL-antagonistic antibody and use thereof |
AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
WO2022207846A1 (en) | 2021-03-31 | 2022-10-06 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101854947A (zh) * | 2007-08-16 | 2010-10-06 | 圣文森特医院悉尼有限公司 | 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法 |
CN102321173A (zh) * | 2011-08-12 | 2012-01-18 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
CN103533951A (zh) * | 2011-04-08 | 2014-01-22 | 安姆根有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢障碍的方法 |
CN104768974A (zh) * | 2012-08-22 | 2015-07-08 | 瑞泽恩制药公司 | GFRα3的人抗体及其使用方法 |
CN105073133A (zh) * | 2012-12-21 | 2015-11-18 | Aveo制药公司 | 抗gdf15抗体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2616362T3 (es) * | 2002-03-05 | 2017-06-12 | Genentech, Inc. | Novedosos polipéptidos que tienen similitud de secuencia con GDNFR y ácidos nucleicos que los codifican |
WO2017121865A1 (en) * | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
-
2016
- 2016-02-29 CN CN201680082844.2A patent/CN108697795A/zh active Pending
- 2016-02-29 JP JP2018540415A patent/JP2019510739A/ja active Pending
- 2016-02-29 WO PCT/CN2016/074809 patent/WO2017147742A1/en active Application Filing
- 2016-02-29 EP EP16891935.5A patent/EP3423094A4/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101854947A (zh) * | 2007-08-16 | 2010-10-06 | 圣文森特医院悉尼有限公司 | 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法 |
CN103533951A (zh) * | 2011-04-08 | 2014-01-22 | 安姆根有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢障碍的方法 |
CN102321173A (zh) * | 2011-08-12 | 2012-01-18 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
CN104768974A (zh) * | 2012-08-22 | 2015-07-08 | 瑞泽恩制药公司 | GFRα3的人抗体及其使用方法 |
CN105073133A (zh) * | 2012-12-21 | 2015-11-18 | Aveo制药公司 | 抗gdf15抗体 |
Non-Patent Citations (2)
Title |
---|
ZHIHUA LI 等: "Identification, expression and functional characterization of the GRAL gene", 《J NEUROCHEM》 * |
刘翾 等: "GDNF家族受体a(GFRa)样蛋白GFRAL在哺乳动物神经细胞的表达和功能研究", 《中国神经科学学会会议论文集》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109069636A (zh) * | 2016-03-04 | 2018-12-21 | 恩格姆生物制药公司 | 用于调节体重的组合物和方法 |
WO2023274276A1 (zh) * | 2021-06-30 | 2023-01-05 | 上海津曼特生物科技有限公司 | 抗gfral抗体及其应用 |
CN116444667A (zh) * | 2023-06-13 | 2023-07-18 | 上海驯鹿生物技术有限公司 | 一种靶向gdf15的全人源抗体及其应用 |
CN116444667B (zh) * | 2023-06-13 | 2023-09-01 | 上海驯鹿生物技术有限公司 | 一种靶向gdf15的全人源抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3423094A1 (en) | 2019-01-09 |
WO2017147742A1 (en) | 2017-09-08 |
EP3423094A4 (en) | 2019-11-06 |
JP2019510739A (ja) | 2019-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108697795A (zh) | Gfral受体疗法 | |
JP6783797B2 (ja) | 抗がん融合ポリペプチド | |
ES2646168T3 (es) | Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 | |
EP1554309A2 (en) | Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics | |
JP2021526012A (ja) | Ctla−4を標的とする抗体、その調製方法および使用 | |
RU2702553C2 (ru) | Новое антитело против tie-2 человека | |
KR20130062280A (ko) | Trail r2 특이적 다량체 스캐폴드 | |
CN109988240B (zh) | 抗gpc-3抗体及其用途 | |
EA021584B1 (ru) | Ингибитор рецептора фактора роста фибробластов-3 (fgfr-3) и его применение | |
JP2008540339A (ja) | Nogoレセプター機能モチーフおよびそれに関するペプチド模倣物、ならびにそれらを使用する方法 | |
JP2020501506A (ja) | 抗NKp46抗体およびその治療的使用 | |
TW201932484A (zh) | 結合alk-1及bmpr-2之雙特異性抗體 | |
CN107531780A (zh) | 抗‑Rho GTPase的构象单域抗体及其用途 | |
KR20210134699A (ko) | 뉴레귤린-4 화합물 및 사용 방법 | |
TW201000129A (en) | Interleukin-21 receptor binding proteins | |
WO2006125632A2 (en) | Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy | |
WO2013140393A1 (en) | Peptides derived from the d1 - domain of nkp46 | |
CN111378040B (zh) | 检测多种恶性肿瘤细胞的抗体及其应用 | |
CN112105629A (zh) | 调节性t细胞表面抗原的表位以及与其特异性结合的抗体 | |
JP2023554351A (ja) | 新規の徐放性プロドラッグ | |
US20060024314A1 (en) | Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics | |
KR20220048028A (ko) | 항-cd19 항체 및 그의 용도 | |
EP4269588A1 (en) | Anti-epha4 antibody | |
US6872703B2 (en) | Insulin receptor-related receptor binding protein | |
CN107614524A (zh) | 治疗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181023 |